Dr. Strosberg on Quality of Life for Midgut Neuroendocrine Tumors

Jonathan Strosberg, MD
Published: Tuesday, Jan 24, 2017



Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses quality of life in patients with midgut neuroendocrine tumors (NETs).

Patients who were enrolled in the phase III NETTER-1 trial were provided with EORTC C30 and GINET21 questionnaires to assess quality of life for both the 177Lu-Dotatate (Lutathera) arm and the high-dose octreotide (Sandostatin) arm. This preliminary analysis focused on global health quality of life, which is an important quality-of-life endpoint in any cancer, explains Strosberg.

NET-specific symptoms, such as diarrhea, flushing, and pain were also looked at. More patients on the Lutathera arm of the study had improvements in their quality of life compared with high-dose octreotide. Overall, it seems as if the quality of life has improved with Lutathera, says Strosberg.
 


Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses quality of life in patients with midgut neuroendocrine tumors (NETs).

Patients who were enrolled in the phase III NETTER-1 trial were provided with EORTC C30 and GINET21 questionnaires to assess quality of life for both the 177Lu-Dotatate (Lutathera) arm and the high-dose octreotide (Sandostatin) arm. This preliminary analysis focused on global health quality of life, which is an important quality-of-life endpoint in any cancer, explains Strosberg.

NET-specific symptoms, such as diarrhea, flushing, and pain were also looked at. More patients on the Lutathera arm of the study had improvements in their quality of life compared with high-dose octreotide. Overall, it seems as if the quality of life has improved with Lutathera, says Strosberg.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x